PROCESS FOR MAKING VINYL CAPROLACTAM-BASED POLYMERS

Details for Australian Patent Application No. 2002309962 (hide)

Owner ISP INVESTMENTS INC.

Inventors CHUANG, Jui-Chang; SHIH, Jenn, S.; DRZEWINSKI, Michael, A.

Pub. Number AU-A-2002309962

PCT Number PCT/US02/15855

PCT Pub. Number WO2003/004541

Priority 09/900,346 06.07.01 US

Filing date 17 May 2002

Wipo publication date 21 January 2003

International Classifications

C08F 026/08 Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen

C08F 020/54 Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide, or nitrile thereof

Event Publications

19 December 2002 Complete Application Filed

  Priority application(s): 09/900,346 06.07.01 US

22 May 2003 Application Open to Public Inspection

  Published as AU-A-2002309962

8 April 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002309963-Use of NF-KAPPA-B inhibitors to treat dry eye disorders

2002309961-METHODS AND FORMULATIONS OF USING A1 ADENOSINE AND P2X PURINORECEPTOR ANTAGONISTS